Additional Description:
KBI Biopharma has deep experience developing purification processes for a wide range of biotherapeutics, including monoclonal antibodies, bispecific antibodies, enzymes, Fc fusion proteins, PEGylated proteins, and complex glycoproteins. It supports more than 40 programs a year, spanning first-in-human process development through late-stage development, characterization, and validation, backing over 15 IND submissions annually; drawing on process development experience across more than 75 biomolecules, KBI has refined standard approaches for various protein classes, including monoclonal antibodies, and built a toolbox for resolving distinctive purification challenges.
Leave your rating & comment